IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome

Rheumatology (Oxford). 2020 Feb 1;59(2):442-445. doi: 10.1093/rheumatology/kez284.

Authors

Shima Yasin¹, Krista Solomon¹, Scott W Canna², Charlotte Girard-Guyonvarc'h³, Cem Gabay³, Eduardo Schiffrin⁴, Andrew Sleight⁴, Alexei A Grom¹, Grant S Schulert¹

Affiliations

¹ Division of Rheumatology, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.
² Pediatric Rheumatology & Immunology, Children's Hospital of Pittsburgh/UPMC, Pittsburgh, PA, USA.
³ Rheumatology, Geneva University Hospitals and University of Geneva, Geneva.
⁴ AB2Bio, Lausanne, Switzerland.

No abstract available

Publication types

Case Reports

MeSH terms

Arthritis, Juvenile / complications
Arthritis, Juvenile / drug therapy*
Child
Humans
Intercellular Signaling Peptides and Proteins / therapeutic use*
Macrophage Activation Syndrome / complications
Macrophage Activation Syndrome / drug therapy*
Male
Recombinant Proteins / therapeutic use*
Recurrence
Treatment Outcome

Substances

Intercellular Signaling Peptides and Proteins
Recombinant Proteins
interleukin-18 binding protein

Grants and funding